Last reviewed · How we verify
GroupB:Liposomal bupivacaine and bupivacaine hydrochloride;
GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; is a Small molecule drug developed by Yongtao Sun. It is currently FDA-approved.
At a glance
| Generic name | GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; |
|---|---|
| Sponsor | Yongtao Sun |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; CI brief — competitive landscape report
- GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; updates RSS · CI watch RSS
- Yongtao Sun portfolio CI
Frequently asked questions about GroupB:Liposomal bupivacaine and bupivacaine hydrochloride;
What is GroupB:Liposomal bupivacaine and bupivacaine hydrochloride;?
GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; is a Small molecule drug developed by Yongtao Sun.
Who makes GroupB:Liposomal bupivacaine and bupivacaine hydrochloride;?
GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; is developed and marketed by Yongtao Sun (see full Yongtao Sun pipeline at /company/yongtao-sun).
What development phase is GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; in?
GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; is FDA-approved (marketed).